JP2021500880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500880A5 JP2021500880A5 JP2020521360A JP2020521360A JP2021500880A5 JP 2021500880 A5 JP2021500880 A5 JP 2021500880A5 JP 2020521360 A JP2020521360 A JP 2020521360A JP 2020521360 A JP2020521360 A JP 2020521360A JP 2021500880 A5 JP2021500880 A5 JP 2021500880A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- adenovirus vector
- expression cassette
- monkey adenovirus
- saladenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000701161 unidentified adenovirus Species 0.000 claims description 38
- 241000282693 Cercopithecidae Species 0.000 claims description 35
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 108700019146 Transgenes Proteins 0.000 claims description 4
- 230000001124 posttranscriptional effect Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 241001217856 Chimpanzee adenovirus Species 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572944P | 2017-10-16 | 2017-10-16 | |
| US62/572,944 | 2017-10-16 | ||
| PCT/EP2018/078210 WO2019076880A1 (en) | 2017-10-16 | 2018-10-16 | SIMIENS ADENOVIRAL VECTORS COMPRISING TWO EXPRESSION CASSETTES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021500880A JP2021500880A (ja) | 2021-01-14 |
| JP2021500880A5 true JP2021500880A5 (cg-RX-API-DMAC7.html) | 2021-11-25 |
Family
ID=63896161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521360A Ceased JP2021500880A (ja) | 2017-10-16 | 2018-10-16 | ２つの発現カセットを有するサルアデノウイルスベクター |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200299651A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3697918B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021500880A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111479926A (cg-RX-API-DMAC7.html) |
| AR (1) | AR114989A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020007413A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3084346A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020003746A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019076880A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7454645B2 (ja) | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン並びにその作製方法及び使用方法 |
| IL315295A (en) | 2019-09-30 | 2024-10-01 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
| TW202144570A (zh) * | 2020-01-28 | 2021-12-01 | 美商科達金尼克斯有限公司 | 去最佳化(DEOPTIMIZED)SARS-CoV-2及其方法及用途 |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| CA2562893A1 (en) * | 2004-04-28 | 2005-11-10 | The Trustees Of The University Of Pennsylvania | Polyvalent viral vectors and a system for production thereof |
| WO2008095027A2 (en) | 2007-01-30 | 2008-08-07 | Cedars-Sinai Medical Center | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene |
| EP2181121A4 (en) | 2007-03-21 | 2012-07-11 | Id Biomedical Corp Quebec | CHIMÄRE ANTIGENE |
| CA2738654C (en) | 2008-09-27 | 2019-02-26 | Witricity Corporation | Wireless energy transfer systems |
| EP3385387B1 (en) | 2009-02-02 | 2021-08-25 | GlaxoSmithKline Biologicals SA | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| WO2012021730A2 (en) * | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
| WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| CN103492574B (zh) | 2011-02-22 | 2015-12-09 | 加州理工学院 | 使用腺相关病毒（aav）载体递送蛋白 |
| EP2764011B1 (en) * | 2011-10-05 | 2021-04-07 | GenVec, Inc. | Adenoviral vector-based respiratory syncytial virus (rsv) vaccine |
| MX384992B (es) * | 2014-06-13 | 2025-03-14 | Glaxosmithkline Biologicals Sa | Combinaciones inmunógenas. |
| BE1024420B1 (fr) | 2015-06-12 | 2018-02-19 | Glaxosmithkline Biologicals Sa | Polynucleotides et polypeptides d'adenovirus |
| GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| BE1024774B1 (fr) | 2016-09-29 | 2018-07-02 | Glaxosmithkline Biologicals Sa | Compositions et procedes de traitement |
-
2018
- 2018-10-16 CN CN201880081337.6A patent/CN111479926A/zh active Pending
- 2018-10-16 EP EP18789094.2A patent/EP3697918B1/en active Active
- 2018-10-16 WO PCT/EP2018/078210 patent/WO2019076880A1/en not_active Ceased
- 2018-10-16 BR BR112020007413-6A patent/BR112020007413A2/pt not_active IP Right Cessation
- 2018-10-16 US US16/756,377 patent/US20200299651A1/en not_active Abandoned
- 2018-10-16 JP JP2020521360A patent/JP2021500880A/ja not_active Ceased
- 2018-10-16 CA CA3084346A patent/CA3084346A1/en not_active Abandoned
- 2018-10-16 MX MX2020003746A patent/MX2020003746A/es unknown
- 2018-10-16 AR ARP180103001A patent/AR114989A1/es not_active Application Discontinuation
-
2023
- 2023-08-21 US US18/453,078 patent/US12180512B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chang | Adenovirus vectors: excellent tools for vaccine development | |
| JP2017514483A5 (cg-RX-API-DMAC7.html) | ||
| JP2021500880A5 (cg-RX-API-DMAC7.html) | ||
| Tatsis et al. | Adenoviruses as vaccine vectors | |
| JP2014512171A5 (cg-RX-API-DMAC7.html) | ||
| RU2016146664A (ru) | Аденовирус, содержащий альбумин-связывающий участок | |
| JP2016538885A5 (cg-RX-API-DMAC7.html) | ||
| JP2014503206A5 (cg-RX-API-DMAC7.html) | ||
| JP2018520997A5 (cg-RX-API-DMAC7.html) | ||
| JP2019526580A5 (cg-RX-API-DMAC7.html) | ||
| JP2018537984A5 (cg-RX-API-DMAC7.html) | ||
| JP2016539946A5 (cg-RX-API-DMAC7.html) | ||
| BR112014000627B1 (pt) | Polipeptídeo mutante, proteínas de fusão, molécula de ácido nucleico, vetor, processo de produção do vetor, célula hospedeira, processo para produção recombinante, composição e kit | |
| JP2015506179A5 (cg-RX-API-DMAC7.html) | ||
| CA2863964A1 (en) | Compartmentalized method of nucleic acid delivery and compositions and uses thereof | |
| RU2019100525A (ru) | Векторная система на основе аденоассоциированного вируса | |
| CN113226364A (zh) | 组合物和方法 | |
| Nguyen et al. | Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers | |
| JP2020537525A5 (cg-RX-API-DMAC7.html) | ||
| JP2020537526A5 (cg-RX-API-DMAC7.html) | ||
| Bisgin et al. | Current update on severe acute respiratory syndrome coronavirus 2 vaccine development with a special emphasis on gene therapy viral vector design and construction for vaccination | |
| Penghui et al. | Oncolytic activity of a novel influenza A virus carrying granulocyte-macrophage colony-stimulating factor in hepatocellular carcinoma | |
| JP2020527167A5 (cg-RX-API-DMAC7.html) | ||
| Kolyasnikova et al. | Anti-cancer virotherapy in Russia: lessons from the past, current challenges and prospects for the future | |
| CN111527213A (zh) | 具有两个编码rsv抗原蛋白或片段的表达盒的腺病毒载体 |